Urea Compounds for CNS/PNS Disorders
Summary
The European Patent Office has published patent application EP4630404A1 detailing urea compounds as activators of potassium channels KV7.2/7.3. These compounds are intended for the treatment of Central Nervous System (CNS) and Peripheral Nervous System (PNS) disorders. The application was filed by Angelini Pharma S.P.A.
What changed
European Patent Application EP4630404A1, published on March 11, 2026, describes novel urea compounds developed by Angelini Pharma S.P.A. These compounds function as activators of potassium channels KV7.2/7.3, offering potential therapeutic applications for Central Nervous System (CNS) and Peripheral Nervous System (PNS) disorders. The application details specific chemical structures and their utility in treating neurological conditions.
This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it signifies potential future intellectual property and market exclusivity for Angelini Pharma S.P.A. in the specified therapeutic areas. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in CNS/PNS drug development, should note this patent filing as it may impact future research, development, and commercialization strategies.
Source document (simplified)
UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS
Publication EP4630404A1 Kind: A1 Mar 11, 2026
Applicants
ANGELINI PHARMA S.P.A.
Inventors
GAROFALO, Barbara, OMBRATO, Rosella, PRATI, Federica, PALLIN, Thomas David, KNIGHT, Jamie David, SAVY, Pascal
IPC Classifications
C07D 213/40 20060101AFI20240614BHEP C07D 213/64 20060101ALI20240614BHEP C07D 213/74 20060101ALI20240614BHEP C07D 213/75 20060101ALI20240614BHEP A61P 25/00 20060101ALI20240614BHEP A61K 31/44 20060101ALI20240614BHEP C07D 217/24 20060101ALI20240614BHEP C07D 221/04 20060101ALI20240614BHEP C07D 239/34 20060101ALI20240614BHEP C07D 401/04 20060101ALI20240614BHEP C07D 401/12 20060101ALI20240614BHEP C07D 405/12 20060101ALI20240614BHEP C07D 409/12 20060101ALI20240614BHEP C07D 413/12 20060101ALI20240614BHEP C07D 471/04 20060101ALI20240614BHEP A61K 31/4427 20060101ALI20240614BHEP A61K 31/472 20060101ALI20240614BHEP A61K 31/506 20060101ALI20240614BHEP A61K 31/5377 20060101ALI20240614BHEP C07D 493/08 20060101ALI20240614BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.